Table 1 Study population and samples that were investigated for the presence of PaCSs

1

M/64

CML, BCR/ABL positive

U

BM, PB

2

M/38

CML, BCR/ABL positive

U

BM

3

F/24

CML, BCR/ABL positive

U

PB

4

F/79

CML, BCR/ABL positive

U

PB

5

F/78

CML, BCR/ABL positive

U

PB

6

F/65

CML, BCR/ABL positive

U

PB

7

F/79

CML, BCR/ABL positive

R

PB

8

F/74

CML, BCR/ABL positive

R

PB

9

F/45

ET

U

BM, PB

10

M/56

PV

U

BM, PB

11

M/79

PV

U

BM, PB

12

M/68

PMF

U

BM, PB

13

F/57

PMF

U

BM

14

F/43

AML not otherwise specified, acute myelomonocytic leukemia (A mutation of NPM1 and internal tandem duplication of FLT3)

U

BM

15

M/64

AML not otherwise specified, acute myelomonocytic leukemia (A mutation of NPM1)

U

BM

16

F/64

AML not otherwise specified, acute monoblastic/monocytic leukemia (A mutation of NPM1)

U

BM

17

F/48

AML not otherwise specified, AML with minimal differentiation (A mutation of NPM1)

U

BM

18

M/64

AML not otherwise specified, AML with minimal differentiation (A mutation of NPM1)

U

BM

19

F/18

AML not otherwise specified, AML with minimal differentiation

U

BM

20

M/23

AML not otherwise specified, acute megakaryoblastic leukemia

U

BM

21

M/35

AML not otherwise specified, AML with minimal differentiation (internal tandem duplication of FLT3)

R

BM

22

M/74

MDS, refractory cytopenia with multilineage dysplasia

U

BM, PB

23

M/69

MDS, refractory cytopenia with multilineage dysplasia

U

BM, PB

24

F/35

MDS, refractory anemia with excess blasts

U

BM, PB

25

M/75

MDS, refractory cytopenia with multilineage dysplasia

U

PB

26

M/75

MDS, refractory cytopenia with multilineage dysplasia

U

PB

27

M/52

MDS, refractory anemia with excess blasts

U

PB

28

M/4

MDS, childhood MDS

U

BM

29

F/37

MDS, refractory thrombocytopenia

U

BM, PB

30

M/49

Hairy cell leukemia

U

BM

31

F/50

Chronic lymphocytic leukemia

U

BM, PB

32

M/50

Plasma cell myeloma

U

BM

33

M/80

Plasma cell myeloma

U

BM